Last reviewed · How we verify
NCT06837961
LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases
Phase 3 trial testing LC-Plasma in Healthy Volunteer in 241 participants. Completed in 3 November 2025.
3 November 2025
Quick facts
| Lead sponsor | RDC Clinical Pty Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 241 |
| Start date | 29 April 2025 |
| Primary completion | 3 November 2025 |
| Estimated completion | 3 November 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- LC-Plasma
- Placebo
Conditions studied
- Healthy Volunteer — all drugs for Healthy Volunteer →
- Immune Response — all drugs for Immune Response →
Sponsor
RDC Clinical Pty Ltd — full company profile →
Who can join
Adults 18 to 60, any sex, with Healthy Volunteer or Immune Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to evaluate the effects of LC-Plasma on the innate and acquired immune systems, including the activation of pDCs, which play a role in virus elimination, as well as to assess its efficacy in reducing clinical symptoms of upper respiratory infectious diseases in healthy adults. Researchers will compare LC-Plasma to placebo, participants will take a tablet containing LC-Plasma or placebo daily for 4 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06837961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LC-Plasma
Trials testing the same drug.
- NCT06827327 — LC-Plasma for Preventing URTIs and Reducing Symptoms · Phase 3 · completed
Other recruiting trials for Healthy Volunteer
Currently open trials in the same condition.
- NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
- NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
- NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
- NCT07439263 — Single Ascending Dose Study of HB2198 in Healthy Participants · Phase 1 · recruiting
- NCT07220122 — Impact of Exogenous Ketones on Breathing in Healthy Volunteers · EARLY_PHASE1 · recruiting
Other RDC Clinical Pty Ltd trials
Trials by the same sponsor.
- NCT06878001 — CaroRite™ for Skin Health and Signs of Ageing · Phase 4 · completed
- NCT06907680 — M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis · Phase 2 · completed
- NCT06827327 — LC-Plasma for Preventing URTIs and Reducing Symptoms · Phase 3 · completed
- NCT06840080 — OEA and LipiSperse Metabolic Study · Phase 4 · completed
- NCT06444763 — Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06837961 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RDC Clinical Pty Ltd
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06837961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing